Targeted Therapy for Non–Small Cell Lung Cancer

This article provides an updated review of the management of oncogene-driven non–small cell lung cancer. The use of targeted therapies for lung cancer driven by EGFR, ALK, ROS1, RET, NTRK, HER2, BRAF, MET, and KRAS are discussed, both in the first-line setting and in the setting of acquired resistance.